NEW YORK – Natera officials said on Tuesday that the company processed more than 1 million tests in 2020, among them about a million for the reproductive health business alone. The company also exceeded its pre-pandemic goals for growing its Prospera transplant testing business while launching its Signatera cancer test and securing reimbursement for it.